Skip to main content

Dermapharm Value Stock - Dividend - Research Selection

Dermapharm Holding

ISIN: DE000A2GS5D8, WKN: A2GS5D

Market price date: 13.07.2021
Market price: 67,40 EUR




Dermapharm Holding Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 20-04-2021
Cash flow
Net operating cash flow 131.098.000
Capital Expenditures -40.796.000
Free cash flow 90.302.000
Balance sheet
Total Equity 321.966.000
Liabilities & Shareholders equity 1.224.400.000
Income statement
Net income 85.826.000
Eps (diluted) 1,594
Diluted shares outstanding 53.840.000
Net sales/revenue 793.829.000

Fundamental ratios calculated on: 13-07-2021

Ratios
Key figures 13-07-2021
Cash flow
P/C 26,90
   
P/FC 39,05
Balance sheet
ROI7,01
ROE26,30
Income statement
P/E41,09
Div. Yield0,00%
P/B10,95
P/S4,44


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolDMP.XETRA
Market Capitalization4.277.161.984,00 USD
Country
IndicesCDAX,Prime All Share,SDAX
Sectors
Raw Data SourceIFRS in Millionen EUR
Stock Split
Internetwww.dermapharm.de


Description of the company

Dermapharm Holding SE engages in the healthcare and pharmaceuticals businesses primarily in Europe. It operates through Branded Pharmaceuticals and Other Healthcare Products, and Parallel Import Business segments. It develops, manufactures, and markets generic and over-the-counter (OTC)pharmaceuticals, natural remedies, and other healthcare products. It offers systemic corticoids to treat allergic reactions, skin disease, and inflammation under the Prednisolut brand; Ampho Moronal, an antifungal drug to treat mouth, throat, and gastrointestinal diseases; Solacutan to treat keratinization; Keltican to treat back pain; and Tromcardin to treat cardiac arrhythmia. It also provides Dekristol, a vitamin D compound; sikapur, a dietary supplement to enhance skin, hair, and nails; VITA aktiv B12 Direktsticks, a galenic form of vitamin B12 with protein compounds to enhance energy and performance, and combats fatigue; and vitamin D drops and silica healthcare products under the Hubner brand. In addition, it offers Panthenol Augensalbe JENAPHARM, an eye ointment; other antibiotics or corticosteroid eye ointments and drops under the Prednifluid, Dexafluid, and Oxyteracyclin-Augensalbe JENAPHARM brands; Dienovel, a hormonal oral contraceptives to prevent pregnancy and treat acne; and Lactofem, a lactic acid treatment. Further, it provides drugs to treat bone loss and cardiovascular diseases; Simagel to treat stomach ailments; Temagin pac, a pain medication; and anesthetics under the Xylocitin-loc or Procain JENAPHARM names. Additionally, it imports and sells pharmaceuticals to wholesalers and pharmacies under the axicorp brand; and offers phytopharmaceuticals, homoeopathics, cosmetics, food and body care products, nutritional supplements, and diet and medical devices. It also operates 16 sales outlets and an online shop; and provides related services. The company was founded in 1991 and is headquartered in Grünwald, Germany. The company is a subsidiary of Themis Beteiligungs-AG.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.dermapharm.de